In the U.S., no cancer drug can be given to patients without FDA approval — but four special pathways can move promising therapies from lab to clinic much faster.
The FDA's Accelerated Review Pathways
Before any new oncology drug reaches a patient, the U.S. Food and Drug Administration must be convinced it is both safe and effective. That review can take years — time that patients facing aggressive or treatment-resistant cancers often don't have. To close that gap, the FDA maintains four accelerated pathways.
Priority Review shortens the standard review clock for drugs that offer a meaningful improvement over existing therapies for serious conditions. Breakthrough Therapy designation is reserved for drugs whose early clinical data already look substantially better than current treatments — it comes with intensive FDA guidance during development. Fast Track eases the development process itself for treatments targeting serious diseases with unmet needs, allowing rolling submission of data as it becomes available. Accelerated Approval lets the FDA greenlight a drug based on a surrogate endpoint — a measurable marker, such as tumor shrinkage, that is reasonably likely to predict real clinical benefit — rather than waiting for longer-term outcomes data.
To qualify for Priority Review specifically, a drug must demonstrate efficacy against a serious disease, present solid safety evidence, and show documented improvement in patient outcomes in critical clinical situations.
Six Agents That Earned the Designation
Several oncology drugs have received Priority Review status, reflecting the breadth of modern cancer treatment approaches:
- Apalutamide (Erleada) — for non-metastatic castration-resistant prostate cancer, a tumor that continues to progress locally despite standard hormone therapy
- Dabrafenib (Tafinlar, Novartis) — a BRAF inhibitor used in certain mutation-driven cancers
- Daratumumab (Darzalex, Janssen/Genmab) — a monoclonal antibody targeting the CD38 protein found on tumor cells
- Iobenguane I-131 (Azedra, Progenics Pharmaceuticals) — a targeted internal radiotherapy agent that exploits the norepinephrine reuptake pathway to deliver radiation directly to certain tumors
- Osimertinib (Tagrisso, AstraZeneca) — a third-generation EGFR tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer
- Pembrolizumab (Keytruda, Merck) — an anti-PD-1 checkpoint inhibitor that restores the immune system's ability to recognize and attack cancer cells
These six agents span surgery-sparing systemic therapies, targeted molecular drugs, immunotherapy, and even a form of internal radiation — a reminder that "cancer treatment" now encompasses far more than any single approach.
The overarching goal of every accelerated pathway is the same: shrink the distance between a scientific breakthrough and the patient who needs it, without sacrificing the rigor that keeps new treatments safe.